Abstract
Resilience, a venture-backed biopharmaceutical manufacturing services firm, has launched with an announcement of $800 million in the bank, a roster of highly accomplished leaders, and an intent to develop “powerful new technologies” that will define the future of therapeutics. The firm’s stated goal is to be a first-of-its-kind provider of production services for cutting-edge biologics, including cell and gene therapies, viral vectors, vaccines, and proteins. But some industry watchers see it as just another contract development and manufacturing organization (CDMO), albeit a high-tech one. “We created Resilience to reimagine biopharmaceutical manufacturing through unprecedented investment in technology and a best-in-class team to execute our vision,” says Robert Nelsen, chairman of Resilience’s board and managing director at Arch Venture Partners, which led a recent series B financing round that netted about $750 million. As a first step, Resilience has acquired Therapure Biopharma, a biologics services firm in Mississauga, Ontario, that observers say
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
